Rasagiline - NDSRI's
References
FAQ's
References
- Youdim, Moussa B. H.; Finberg, John P. M.; Levy, Ruth; Sterling, Jeffrey; Lerner, David; Berger-Paskin, Tirtsah, R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it, Teva Pharmaceutical Industries Ltd., Israel and Technion Research and Development Foundation Ltd., Israel, EP436492B1, June 8, 1994
- Ma, Jinfei; Chen, Xiaoyan; Duan, Xiaotao; Deng, Pan; Wang, Hui; Zhong, Dafang, Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 873, Issue: 2, Pages: 203-208, 2008
Frequently Asked Questions
Can Rasagiline impurities affect the effectiveness of the drug?
Yes, Rasagiline impurities can affect the drug's effectiveness as they can alter its pharmacological properties and lead to variations in therapeutic response.
Do regulatory authorities regulate Rasagiline impurities?
Yes, Rasagiline impurities are regulated by authorities to ensure the safety and quality of the medication.
What is the significance of controlling Rasagiline impurities?
The significance of controlling Rasagiline impurities is to ensure the safety, efficacy, and quality of the medication, as impurities can potentially affect its therapeutic effectiveness and may pose health risks to patients.
What are the temperature conditions required to store Rasagiline impurities?
Rasagiline impurities should be stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.